Akari Therapeutics participates in Virtual Investor “Why Now” on-demand conference webcast - AKTX News | RalliesAkari Therapeutics participates in Virtual Investor “Why Now” on-demand conference webcast
A
AKTX• Akari Therapeutics participates in Virtual Investor conference
- Akari Therapeutics participated in the Virtual Investor “Why Now” on-demand conference.
- CEO Abizer Gaslightwala outlined an investment thesis tied to rising demand for differentiated ADC payload technologies.
- Presentation emphasized the company’s PH1 RNA-splicing payload platform as a potential alternative to conventional ADC payloads.
